These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 19504141)

  • 1. Comparing the antiplatelet effect of clopidogrel hydrogensulfate and clopidogrel besylate: a crossover study.
    Neubauer H; Krüger JC; Lask S; Endres HG; Pepinghege F; Engelhardt A; Bulut D; Mügge A
    Clin Res Cardiol; 2009 Sep; 98(9):533-40. PubMed ID: 19504141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of clopidogrel besylate and clopidogrel hydrogensulfate on platelet aggregation in patients with coronary artery disease: a retrospective study.
    Borsiczky B; Sarszegi Z; Konyi A; Szabados S; Gaszner B
    Thromb Res; 2012 Jun; 129(6):700-3. PubMed ID: 21924759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the antiplatelet effect of clopidogrel hydrogenosulfate and clopidogrel besylate in patients with stable coronary artery disease.
    Hamilos M; Saloustros I; Skalidis E; Igoumenidis N; Kambouris M; Chlouverakis G; Vougia D; Loggakis I; Vardas PE; Kochiadakis G
    J Thromb Thrombolysis; 2015 Oct; 40(3):288-93. PubMed ID: 25662861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects.
    Kim SD; Kang W; Lee HW; Park DJ; Ahn JH; Kim MJ; Kim EY; Kim SW; Nam HS; Na HJ; Yoon YR
    Clin Ther; 2009 Apr; 31(4):793-803. PubMed ID: 19446152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole blood aggregometry for evaluation of the antiplatelet effects of clopidogrel.
    Hochholzer W; Trenk D; Frundi D; Neumann FJ
    Thromb Res; 2007; 119(3):285-91. PubMed ID: 16603231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and the antiplatelet effect of a new clopidogrel formulation, clopidogrel besylate, in healthy subjects.
    Park JY; Kim KA; Ryu JH; Lee GH; Jeon SH; Kim JS
    Int J Clin Pharmacol Ther; 2010 Apr; 48(4):259-69. PubMed ID: 20353747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of clopidogrel besylate on platelet reactivity in patients with acute coronary syndromes. Comparison with clopidogrel hydrogen sulfate.
    Tsoumani ME; Kalantzi KI; Dimitriou AA; Ntalas IV; Goudevenos IA; Tselepis AD
    Expert Opin Pharmacother; 2012 Feb; 13(2):149-58. PubMed ID: 22188544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiplatelet efficacy of long-term treatment with clopidogrel besylate in patients with a history of acute coronary syndrome: comparison with clopidogrel hydrogen sulfate.
    Tsoumani ME; Kalantzi KI; Dimitriou AA; Ntalas IV; Goudevenos IA; Tselepis AD
    Angiology; 2012 Oct; 63(7):547-51. PubMed ID: 22144668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative pharmacokinetics/pharmacodynamics of clopidogrel besylate and clopidogrel bisulfate in healthy Korean subjects.
    Kim BH; Kim JR; Lim KS; Shin HS; Yoon SH; Cho JY; Jang IJ; Shin SG; Yu KS
    Clin Drug Investig; 2012 Dec; 32(12):817-26. PubMed ID: 23026843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Doubling the clopidogrel dose in patients with reduced responsiveness to the standard dose is associated with a limited effectiveness as evaluated by impedance aggregometry.
    Stellbaum C; Ayral Y; Morguet A; Schultheiss HP; Rauch U
    Cardiovasc Revasc Med; 2012; 13(3):159-66. PubMed ID: 22503564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationships between optical aggregometry (type born) and flow cytometry in evaluating ADP-induced platelet activation.
    Sbrana S; Della Pina F; Rizza A; Buffa M; De Filippis R; Gianetti J; Clerico A
    Cytometry B Clin Cytom; 2008 Jan; 74(1):30-9. PubMed ID: 17630652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the antiplatelet effect of clopidogrel benzene sulfonate and clopidogrel hydrogen sulfate in stable coronary heart disease.
    Wang SH; Li X; Hou FL; Tian YJ; Liu YH; Zheng SL
    Genet Mol Res; 2016 Apr; 15(2):. PubMed ID: 27173230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The effects of post coronary stenting triple antiplatelet therapies on platelet functions].
    Han YL; Su QF; Li Y; Kang J; Yan CH; Wang SL
    Zhonghua Nei Ke Za Zhi; 2006 Aug; 45(8):635-8. PubMed ID: 17074146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Switching from clopidogrel hydrogen sulfate to clopidogrel besylate. Impaired antiplatelet effect in patients with ischemic stroke].
    Meves SH; Overbeck U; Kaiser A; Krogias C; Neubauer H
    Nervenarzt; 2010 Aug; 81(8):992-7. PubMed ID: 20517690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry.
    Jakubowski JA; Payne CD; Li YG; Farid NA; Brandt JT; Small DS; Salazar DE; Winters KJ
    Thromb Haemost; 2008 Jan; 99(1):215-22. PubMed ID: 18217157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Platelet responsiveness to clopidogrel in patients with coronary syndrome. Comparison of platelet aggregation induced by ADP and flow cytometric analysis of intraplatelet VASP phosphorylation].
    Morel O; Viellard C; Faure A; Jesel L; Ohlmann P; Desprez D; Chauvin M; Roul G; Grunebaum L; Bareiss P
    Ann Cardiol Angeiol (Paris); 2007 Jan; 56(1):21-9. PubMed ID: 17343035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy.
    Kastrati A; von Beckerath N; Joost A; Pogatsa-Murray G; Gorchakova O; Schömig A
    Circulation; 2004 Oct; 110(14):1916-9. PubMed ID: 15262828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of 150-mg vs 300-mg loading doses of clopidogrel on platelet function in Japanese patients undergoing coronary stent placement.
    Fukushima K; Kobayashi Y; Kitahara H; Iwata Y; Nakayama T; Kuroda N; Ooyama M; Nomura F; Komuro I
    Circ J; 2008 Aug; 72(8):1282-4. PubMed ID: 18654014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation.
    Brandt JT; Payne CD; Wiviott SD; Weerakkody G; Farid NA; Small DS; Jakubowski JA; Naganuma H; Winters KJ
    Am Heart J; 2007 Jan; 153(1):66.e9-16. PubMed ID: 17174640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study.
    Jeong YH; Lee SW; Choi BR; Kim IS; Seo MK; Kwak CH; Hwang JY; Park SW
    J Am Coll Cardiol; 2009 Mar; 53(13):1101-9. PubMed ID: 19324253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.